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lesion. Addition of proliferating cell nuclear antigen to DNA polymerase i and replication protein A to DNA polymerase a did not restore their capacity to elongate past the adduct. On the other hand, DNA polymerase 13 efficiently bypassed the cisplatin adduct. Furthermore, we observed that DNA polymerase ,B was the only polymerase capable of primer extension of a 3'-OH located opposite the base preceding the lesion.
Likewise, DNA polymerase 18 was able to elongate the arrested replication products of the other three DNA polymerases, thus showing its capacity to successfully compete with polymerases a, 6 , and E in the stalled replication complex. Our data suggest (i) a possible mechanism enabling DNA polymerase 13 to bypass a d(GpG)-cisplatin adduct in vitro and (ii) a role for this enzyme in processing DNA damage in vivo.
Among the possible mechanisms of mutagenesis is error-prone replication by cellular DNA polymerases past a DNA lesion followed by fixation of the mutation during subsequent rounds of replication. In eukaryotic cells, it is still unclear whether the replicative DNA polymerases a, 8 , and E can carry out translesion synthesis either alone or with the help of accessory proteins. Alternatively, a separate DNA polymerase may be required for this process. For example, genetic evidence in the yeast Saccharomyces cerevisiae indicates that a putative DNA polymerase, the product of the REV3 gene, may be involved in error-prone translesion synthesis but not in normal DNA replication (1) . DNA polymerase (3 is one of the five mammalian polymerases identified to date and is believed to function primarily in the repair of damaged DNA (2) . However, DNA polymerase a may also have a role in replicative synthesis, since the enzyme can substitute for DNA polymerase I during DNA replication in Escherichia coli (3) , and it is required for the conversion of single-stranded M13 DNA to double-stranded DNA in Xenopus oocytes and in oocyte nuclear extracts (4) .
cis-Diamminedichloroplatinum(II) (cisplatin) is an anticancer agent widely used in the treatment of ovarian, testicular, head, and neck carcinomas (5) . It is believed that this compound exerts its cytotoxic properties by forming stable lesions on DNA, primarily intrastrand cross-links at the N-7 positions of adjacent guanine bases [d(GpG)-cisplatin or Pt-d(GpG)] (6). Replicative bypass of cisplatin adducts has been described in bacteria (7, 8) and in eukaryotic cells (9) . Recent work in our laboratory has demonstrated that a single-stranded DNA The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
vector bearing a unique intrastrand bifunctional adduct Ptd(GpG) at codon 13 of the human protooncogene HRAS is replicated in simian COS-7 cells and that such translesion synthesis may be mutagenic (10) .
To our knowledge, the capacities of the major mammalian replication enzymes to bypass the Pt-d(GpG) lesion have not been compared. To address this question, we have investigated the ability of purified calf thymus DNA polymerases a, (3, 8 , and s to catalyze in vitro the bypass synthesis of a single Pt-d(GpG) adduct placed on codon 13 of the human HRAS protooncogene, the same sequence used for our previous in vivo studies (10 were annealed by mixing an excess of the 14-mer, 52-mer, and 5'-phosphorylated 38-mer with either the 5'-phosphorylated 8-mer or-the 5'-phosphorylated 8-mer-Pt adduct oligonucleotides, which had been purified and characterized as described (16) . After ligation the resulting 60-mer or 60-mer-Pt substrates were purified on a 20% polyacrylamide/7 M urea/30% formamide denaturing gel. These templates contain the sequence of the protooncogene HRAS from codon 7 to codon 14 (nucleotide 2 to nucleotide 25). For DNA synthesis assays, these templates were hybridized to a 5'-32P-labeled 17-mer synthetic primer situated at nucleotides 44-60 (Fig. 1A) .
In vitro DNA Replication Assays. (17) and migrated on the gel next to the reaction products. The printed sequence on the left side corresponds to the template containing the Pt adduct (k!). Pol indicates DNA polymerases.
MgCl2; and 500 ,uM each of dATP, dCTP, dGTP, and dTTP.
At the end of the reaction, 5 p,l of stopping buffer (90% formamide/0.1% xylene cyanol/0.1% bromophenol blue/0.1 mM EDTA) was added. Samples were boiled for 5 min and loaded to a 15% polyacrylamide/7 M urea/30% formamide gel. The amounts of templates and enzymes as well as the incubation times are indicated in the figure legends.
RESULTS
Calf Thymus DNA Polymerases a, 8, and E Cannot Bypass the d(GpG)-Cisplatin Adduct Either Separately or in Combination with Accessory Proteins. To study translesion synthesis by DNA polymerases a, 8 , and s, we investigated the extension of a 5'-phosphorylated 17-mer oligonucleotide primer on untreated or cisplatin-damaged 60-mer templates. After these substrates were replicated by the enzymes in the presence of high concentrations of nucleotide triphosphates to maximize the opportunity of bypass events (18) , the newly synthesized DNA products were separated by polyacrylamide gel electrophoresis and visualized by autoradiography (Fig.  1B) . When untreated substrate was used, all of the available primers were extended to full-size (60-mer) products, as expected for efficient replication by the three DNA polymerases. In the case of the cisplatin-modified 60-mer substrate, all of the reaction products migrated as a 39-mer DNA, (Fig. 2A) . Similar results were obtained by performing a kinetic study with 0.12 pmol of template and 15 units of enzyme (Fig. 2B) . Here, one can see that the arrest sites observed at early incubation times were greatly reduced by increasing the length of the reaction. Replication of the 60-mer substrates creates anAci I restriction site, 5'-GCGG-3', which includes the GG sequence bearing the adduct. Following replication of intact and platinated substrates by DNA polymerase X3, the reaction products were subjected to digestion by Aci I. Gel analysis of the digestion products revealed that the full-length products of replication of the platinated 60-mer (but not of unplatinated control template) were resistant to the action of the restriction enzyme (data not shown). Given and s is interrupted. To evaluate this hypothesis, we constructed a 60-mer-Pt substrate hybridized to a 39-nucleotidelong complementary primer, whose 3' dA terminus is positioned opposite the dT base prior to the lesion (see Fig. 3A ). This substrate, as well as the untreated control template, was then extended by DNA polymerases a, 8, s, and (3, and the products were resolved by gel electrophoresis (Fig. 3B) . Efficient primer extension was catalyzed by all enzymes on undamaged substrate, generating a full-length 60-mer product. However, DNA synthesis initiation from the position opposite the cisplatin adduct occurred only when DNA polymerase (3 was used (Fig. 3B, lane f) . In experiments performed under conditions similar to those described for Fig. 3 The data presented so far lead to the question ofwhether DNA polymerase ,B could replicate through the Pt-d(GpG) adduct by competing with the DNA polymerases for the primertemplate junction. Therefore, we decided to test whether DNA polymerase 13 was able to extend the interrupted products of synthesis by DNA polymerases a, 6, and s. Primer extension experiments on cisplatin-damaged 60-mer substrate were first carried out with DNA polymerases a, 8, and -for 2 hr at 37°C as described in Fig. 1 . Only DNA polymerase 13 performed partial DNA translesion synthesis at this pH, which was optimal for DNA polymerases a, 8, and s (Fig. 4, lane 13) . Addition of DNA polymerase (3 Fig. 4) .
These results indicate that in vitro DNA polymerase 13 can replace DNA polymerases a, 8, and s in the stalled replication complex and extend 3' termini of interrupted products through the d(GpG)-cisplatin adduct.
DISCUSSION
Replication of damaged DNA represents a major mechanism for generating mutations. Bypass synthesis of unrepaired lesions at mutagenic hot-spot codons of transforming genes may be an important factor in both the initiation and development of human cancer. Slow repair has been seen in the p53 gene at positions frequently mutated in skin cancer (25) , and the replication machinery may pass through the damaged codons at mutation hot spots with a high frequency of misincorporation. We have recently reported that a vector containing a single Pt-d(GpG) adduct placed on codon 13 of the human HRAS protooncogene was efficiently replicated in monkey cells and that translesion synthesis could contribute to HRASactivating mutations induced by the drug (10) . In the present study, we investigated whether purified eukaryotic DNA polymerases could perform in vitro translesion synthesis on the same platinated sequence used in vivo. For this purpose, we have constructed a 60-mer oligonucleotide containing part of the human HRAS sequence and a well-defined Pt-d(GpG) intrastrand bifunctional adduct at the d(GGT) sequence of codon 13 (see Fig. 1A ).
When we performed primer extension experiments on this damaged template with purified calf thymus DNA polymerases a, 6 , and s, we failed to observe any bypass (see Fig.   1B ). For all of these enzymes, a strong stop was seen at the position one base prior to the adduct site, and we detected no incorporation opposite the damage. The fact that we observed the same arrest position by the three enzymes suggests that the size of the products obtained with DNA polymerases 6 and s is not a consequence of degradation by their proofreading activities, since such activity is not present in the form of the DNA polymerase a used here. Inhibition of DNA polymerase E elongation by a unique Pt-d(GpG) lesion placed on short synthetic oligomers has been described by Huang et at (26) . Our data show that DNA polymerase E inhibition by the biadduct can also be obtained on codon 13 of the human HRAS protooncogene, a hot spot for mutagenesis in vivo.
We further investigated whether accessory factors involved at the eukaryotic DNA replication fork could promote bypass synthesis. RPA, known to reduce DNA polymerase a pausing (21), did not appear to alleviate DNA polymerase a arrest at the site of the lesion. PCNA, which functions to increase the processivity of DNA polymerase 8 and has been shown to promote its bypass synthesis of UV lesions (23), did not help DNA polymerase 6 in replicating the Pt-d(GpG) adduct.
In contrast to polymerases a, 6, and £, DNA polymerase 13 is capable of catalyzing the incorporation of nucleotides across the damaged guanines and of elongating efficiently past the position of the Pt-d(GpG) adduct to reach full-length 60-mer products (Fig. 2) . This finding may implicate DNA polymerase 13 in the previously observed survival of single-stranded simian virus 40-based shuttle vectors bearing the same damaged HRAS sequence (10) .
To our knowledge, there has been no previous report that a purified eukaryotic DNA polymerase can efficiently synthesize past a Pt-d(GpG) adduct, one normally considered to be a strong block to DNA replication. DNA polymerase 1 has been reported to copy past apurinic sites (27) and to synthesize in vitro through a cis-syn thymine dimer placed on codon 61 of HRAS gene (28) ; however, in contrast to what we observed with the Pt-d(GpG) adduct, the translesion replication of a cis-syn dimer does not appear to be specific to DNA polymerase 13, since it is also bypassed by DNA polymerase a (28) and DNA polymerase 6 in the presence of PCNA (23) . It is possible that translesion synthesis observed here may be influenced by the type of lesion and the sequence context. Hence, it remains to be determined whether the bypass observed at codon 13 of the HRAS protooncogene, hot spot for mutagenesis, could be obtained with the same adduct placed on a different codon or for another blocking lesion.
What properties of these enzymes might be responsible for their different capacities to bypass the d(GpG)-cisplatin lesion? One feature that distinguishes DNA polymerase 13 is its small size compared to DNA polymerases a, 6 , and E (29) .
Recently the crystal structure of polymerase 13 has been solved (30, 31) . It showed structural similarity with two other small polymerases with which it has no sequence homology, the Klenow fragment ofE. coli polymerase I [PolI(Kf)] and human immunodeficiency virus (HIV) reverse transcriptase (RT) (32) . We (26) . Given its distributive mode of DNA synthesis (29) , DNA polymerase 3 likely dissociates and reassociates frequently with the substrate. The particular ability of polymerase ,B to catalyze in vitro extension from the position prior to the platinated guanines appears to reflect its capacity to reinitiate DNA replication at the site opposite the adduct, while DNA polymerases a, 8 , and s appear to be unable to reinitiate DNA synthesis at this position (see Fig. 3 ). Furthermore, experiments shown in Fig. 4 indicate that DNA polymerase /3 was able to compete with DNA polymerases a, 6 , and e at the stalled replication complex. We propose that the simple subunit composition of polymerase , (30, 31) may favor reassociation of the enzyme to a primer-template junction with damaged bases. Taken together, our results suggest a possible role of DNA polymerase 13 in the bypass of d(GpG)-cisplatin DNA lesions in vivo. In this respect, it is interesting to note that induction of DNA polymerase (3 mRNA by DNA-damaging agents has been described in CHO cells (35) .
